NCT03400332 2026-02-24
A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers
Bristol-Myers Squibb
Phase 1/2 Completed
Bristol-Myers Squibb
Oslo University Hospital
Bristol-Myers Squibb
Ludwig Institute for Cancer Research
Ardigen
Ardigen
Lytix Biopharma AS